​

Phathom Pharmaceuticals (PHAT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PHAT Stock Forecast

Phathom Pharmaceuticals (PHAT) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $23.83, with a high of $35.00 and a low of $12.00. This represents a 76.00% increase from the last price of $13.54.

$5 $11 $17 $23 $29 $35 High: $35 Avg: $23.83 Low: $12 Last Closed Price: $13.54

PHAT Stock Rating

Phathom Pharmaceuticals stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

PHAT Price Target Upside V Benchmarks

TypeNameUpside
StockPhathom Pharmaceuticals76.00%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$18.00
Last Closing Price$13.54$13.54$13.54
Upside/Downside--32.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25261--9
Sep, 25261--9
Aug, 25261--9
Jul, 25261--9
Jun, 25261--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 07, 2025Guggenheim$18.00$5.06255.73%32.94%
Aug 08, 2024Paul ChoiGoldman Sachs$12.00$11.752.13%-11.37%
Jul 19, 2024Matthew CaufieldH.C. Wainwright$28.00$10.95155.71%106.79%
May 02, 2024Annabel SamimyStifel Nicolaus$24.00$9.76145.90%77.25%
Jan 05, 2024Joseph StringerNeedham$26.00$8.99189.21%92.02%
Jan 04, 2023BMO Capital$35.00$11.99191.91%158.49%
Jan 04, 2023Needham$25.00$11.99108.51%84.64%
Nov 14, 2022BMO Capital$38.00$10.65256.81%180.65%
Nov 11, 2022Guggenheim$30.00$10.78178.29%121.57%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 06, 2025CitigroupBuyBuyhold
May 02, 2025H.C. WainwrightBuyBuyhold
Mar 07, 2025Craig-HallumBuyBuyhold
Aug 08, 2024Goldman SachsNeutralNeutralhold
Jul 19, 2024H.C. WainwrightBuyBuyhold
Jan 05, 2024NeedhamBuyBuyhold
May 11, 2023William BlairMarket Performdowngrade
Jan 04, 2023BMO CapitalOutperformOutperformhold
Jan 04, 2023NeedhamBuyBuyhold
Nov 14, 2022BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-8 $-6 $-4 $-2 $0 $2 $3 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.93$-5.29----
Avg Forecast$-3.72$-5.41$-4.12$-1.61$0.70$1.82
High Forecast$-3.32$-3.78$-2.88$-0.27$1.68$2.48
Low Forecast$-4.12$-7.38$-5.61$-2.31$-0.28$1.27
Surprise %5.65%-2.22%----

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$682.00K$55.25M----
Avg Forecast$394.86K$51.63M$175.07M$383.68M$599.45M$763.24M
High Forecast$437.16K$55.00M$218.32M$391.75M$614.74M$976.80M
Low Forecast$347.85K$46.69M$131.11M$375.62M$584.16M$586.59M
Surprise %72.72%7.02%----

Net Income Forecast

$-400M $-290M $-180M $-70M $40M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-201.59M-----
Avg Forecast$-201.59M$-339.44M$-217.81M$-66.16M$35.90M$93.35M
High Forecast$-170.43M$-193.93M$-147.63M$-13.73M$86.01M$127.30M
Low Forecast$-211.45M$-378.30M$-287.99M$-118.59M$-14.21M$65.26M
Surprise %------

PHAT Forecast FAQ

Is Phathom Pharmaceuticals stock a buy?

Phathom Pharmaceuticals stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Phathom Pharmaceuticals is a favorable investment for most analysts.

What is Phathom Pharmaceuticals's price target?

Phathom Pharmaceuticals's price target, set by 8 Wall Street analysts, averages $23.83 over the next 12 months. The price target range spans from $12 at the low end to $35 at the high end, suggesting a potential 76.00% change from the previous closing price of $13.54.

How does Phathom Pharmaceuticals stock forecast compare to its benchmarks?

Phathom Pharmaceuticals's stock forecast shows a 76.00% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Phathom Pharmaceuticals over the past three months?

  • October 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Phathom Pharmaceuticals’s EPS forecast?

Phathom Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.12, marking a -22.12% decrease from the reported $-5.29 in 2024. Estimates for the following years are $-1.61 in 2026, $0.7 in 2027, and $1.82 in 2028.

What is Phathom Pharmaceuticals’s revenue forecast?

Phathom Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $175.07M, reflecting a 216.86% increase from the reported $55.25M in 2024. The forecast for 2026 is $383.68M, followed by $599.45M for 2027, and $763.24M for 2028.

What is Phathom Pharmaceuticals’s net income forecast?

Phathom Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-218M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-66.161M in 2026, $35.9M in 2027, and $93.35M in 2028.